摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2(R)-N-hydroxy-1-(4-(pyrid-4-yl)oxybenzenesulfonyl)-4-acetylpiperazine-2-carboxamide | 1100803-79-9

中文名称
——
中文别名
——
英文名称
2(R)-N-hydroxy-1-(4-(pyrid-4-yl)oxybenzenesulfonyl)-4-acetylpiperazine-2-carboxamide
英文别名
(2R)-4-acetyl-N-hydroxy-1-(4-pyridin-4-yloxyphenyl)sulfonylpiperazine-2-carboxamide
2(R)-N-hydroxy-1-(4-(pyrid-4-yl)oxybenzenesulfonyl)-4-acetylpiperazine-2-carboxamide化学式
CAS
1100803-79-9
化学式
C18H20N4O6S
mdl
——
分子量
420.446
InChiKey
PELHKZRDUGLSOJ-QGZVFWFLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.3
  • 重原子数:
    29
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.28
  • 拓扑面积:
    138
  • 氢给体数:
    2
  • 氢受体数:
    8

文献信息

  • Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
    申请人:Agouron Pharmaceuticals, Inc.
    公开号:US20030130506A1
    公开(公告)日:2003-07-10
    The invention relates to compounds of the formula 1: 1 wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder are carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of the formula I or a prodrug, salt of solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.
    本发明涉及式1:1的化合物,其中:Z为O或S;V是一个二价基团,与C*和N一起形成具有六个环原子的环,其中除C*和N之外的每个环原子独立地未取代或被适当取代基团取代,且其中至少一个其他环原子是从O、N和S中选择的杂原子,其余是碳原子;Ar是芳基或杂芳基;以及其药学上可接受的前药、盐和溶剂化物。本发明还涉及这些化合物的药学上可接受的前药、盐和溶剂化物。本发明还涉及通过给予式I或其前药、盐或溶剂化物来抑制蛋白酶活性的方法。本发明还涉及包含这些化合物、前药、盐和溶剂化物的有效量的制药组合物。本发明还涉及用于制备这些化合物、前药、盐和溶剂化物的有用方法和中间体。
  • Intermediates useful for the preparation of metallproteinase inhibitors
    申请人:Agouron Pharmaceuticals, Inc.
    公开号:EP1095936B1
    公开(公告)日:2004-11-24
  • US5753653A
    申请人:——
    公开号:US5753653A
    公开(公告)日:1998-05-19
  • US6153757A
    申请人:——
    公开号:US6153757A
    公开(公告)日:2000-11-28
  • US6500948B1
    申请人:——
    公开号:US6500948B1
    公开(公告)日:2002-12-31
查看更多